Updated April 3, 2020, 10 p.m. PT. The following sections have been updated in the past 24 hours: Ophthalmology ties

The Academy is sharing important ophthalmology-specific information related to the novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was previously known by the provisional name 2019-nCoV. The highly contagious virus can cause a severe respiratory disease known as COVID-19.

This page is principally authored by James Chodosh, MD, MPH, with assistance from Gary N. Holland, MD, and Steven Yeh, MD.

What you need to know
Several reports suggest the virus can cause a mild follicular conjunctivitis otherwise indistinguishable from other viral causes, and possibly be transmitted by aerosol contact with conjunctiva.
Patients who present to ophthalmologists for conjunctivitis who also have fever and respiratory symptoms including cough and shortness of breath, and who have recently traveled internationally, particularly to areas with known outbreaks (China, Iran, Italy and South Korea, or to hotspots within the United States), or with family members recently back from one of these areas, could represent cases of COVID-19.
The Academy and federal officials recommend protection for the mouth, nose and eyes when caring for patients potentially infected with SARS-CoV-2.
The virus that causes COVID-19 is very likely susceptible to the same alcohol- and bleach-based disinfectants that ophthalmologists commonly use to disinfect ophthalmic instruments and office furniture. To prevent SARS-CoV-2 transmission, the same disinfection practices already used to prevent office-based spread of other viral pathogens are recommended before and after every patient encounter.

The global outbreak
may due to the following factors: firstly, the unknown
pneumonia outbroke at the time of China Spring Festi-
val, when the mass population flowing. Secondly, more
detailed molecular mechanisms of viral binding and
entry manners await to be elucidated, which may ham-
per the development of targeted therapy. Thirdly, avail-
able data suggested that the SARS-CoV-2 may be less
virulent than the SARS-CoV and MERS-CoV, with the
currently analyzed mortality of COVID-19 is 3.4%, lower
than death rate of SARS (9.6%) and MERS (around
35%), respectively [19]. Thus, the potential mechanisms
for human-to-human transmission and pathogenic
mechanisms of the SARS-CoV-2 are under extensively
studied

Link

Thanks.

Meanwhile,how long does it take to recover from the virus.

What treatment is being administered to manage the symptoms?

Blood type A are the ones who are getting hospitalized most. Blood type O tuko sawa